Evidence map›Paper›PMID 38511952›Full record

Observational studyMicrobiology spectrum2024

Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.

Andreza Parreiras Gonçalves, Letícia Trindade Almeida, Izabela Maurício de Rezende, Jordana Rodrigues Barbosa Fradico, Leonardo Soares Pereira, Dario Brock Ramalho, Marcelo Antônio Pascoal Xavier, Carlos Eduardo Calzavara Silva, Thomas P Monath, Angelle Desiree LaBeaud and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Potential Antiviral Compounds fromMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Andreza Parreiras GonçalvesInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0001-8010-3170
Letícia Trindade AlmeidaInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Izabela Maurício de RezendeDepartment of Pediatrics, Infectious Disease Division, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-2616-6300
Jordana Rodrigues Barbosa FradicoInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Leonardo Soares PereiraDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Dario Brock RamalhoHospital Eduardo de Menezes (HEM), Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Belo Horizonte, Minas Gerais, Brazil.
Marcelo Antônio Pascoal XavierInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Carlos Eduardo Calzavara SilvaInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Thomas P MonathCrozet BioPharma LLC, Lexington, Massachusetts, USA.
Angelle Desiree LaBeaudDepartment of Pediatrics, Infectious Disease Division, Stanford University School of Medicine, Stanford, California, USA.
Betania Paiva DrumondDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-4049-4055
Ana Carolina Campi-AzevedoInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Olindo Assis Martins-FilhoInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Andréa Teixeira-CarvalhoInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.
Pedro Augusto AlvesInstituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-9659-5621
Grupo de Estudos de Pesquisa e Resposta em Febre Amarela do Estado de Minas Gerais
Fundação Oswaldo Cruz · BRUniversidade Federal de Minas Gerais · BRStanford University · USCrozet BioPharma (United States) · USFundação Hospitalar do Estado de Minas Gerais · BR

Funding

Yellow fever in Brazil: new insights on an old diseaseR01AI149614 · NIAID · STANFORD UNIVERSITY · PI FILHO, OLINDO ASSIS MARTINS, LABEAUD, ANGELLE DESIREE · 2020 to 2023
$609k
NIAID NIH HHS R01 AI149614
6 · The paper itself

Abstract

Between 2016 and 2018, Brazil experienced major sylvatic yellow fever (YF) outbreaks that caused hundreds of casualties, with Minas Gerais (MG) being the most affected state. These outbreaks provided a unique opportunity to assess the immune response triggered by the wild-type (WT) yellow fever virus (YFV) in humans. The plaque reduction neutralization test (PRNT) is currently the standard method to assess the humoral immune response to YFV by measuring neutralizing antibodies (nAbs). The present study aimed to evaluate the humoral immune response of patients from the 2017-2018 sylvatic YF outbreak in MG with different disease outcomes by using PRNTs with a WT YFV strain, isolated from the 2017-2018 outbreak, and a vaccine YFV strain. Samples from naturally infected YF patients were tested, in comparison with healthy vaccinees. Results showed that both groups presented different levels of nAb against the WT and vaccine strains, and the levels of neutralization against the strains varied homotypically and heterotypically. Results based on the geometric mean titers (GMTs) suggest that the humoral immune response after a natural infection of YFV can reach higher levels than that induced by vaccination (GMT of patients against WT YFV compared to GMT of vaccinees,

Indexed as

Antibodies, NeutralizingAntibodies, ViralDisease OutbreaksImmunity, HumoralYellow FeverYellow Fever VaccineYellow fever virusAdolescentAdultAgedBrazilFemaleHumansMaleMiddle AgedNeutralization TestsAntibodies, NeutralizingAntibodies, ViralYellow Fever Vaccine17DD YFV strainlate relapsing hepatitis after yellow feverneutralizing antibodiesPRNTsylvatic YFwild-type strainyellow feverYF immune response

Identifiers

PMID38511952
PMCPMC11064539
OpenAlexW4393040407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.